Global Allergy Immunotherapies Supply, Demand and Key Producers, 2026-2032
The global Allergy Immunotherapies market size is expected to reach $ 4396 million by 2032, rising at a market growth of 7.8% CAGR during the forecast period (2026-2032).
Allergy Immunotherapies are disease-modifying therapeutic approaches designed to reduce allergen-specific hypersensitivity by exposing appropriately diagnosed patients to controlled doses of relevant allergens over a defined treatment course, thereby modifying the immune response rather than providing only short-term symptom control. The market covered in this study centers on subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT), and oral immunotherapy (OIT), with commercial products supplied as injectable allergen extracts, sublingual tablets, sublingual drops or solutions, and oral allergen preparations. Products may target single or multiple allergens and are developed from major allergen sources including house dust mites, pollens, insect venoms, animal dander, molds or fungi, and food allergens. Core clinical applications include allergic rhinitis and rhinoconjunctivitis, allergic asthma, Hymenoptera venom allergy, and food allergy. Product performance and commercial positioning depend strongly on allergen characterization, extract standardization, dose consistency, formulation stability, safety, administration convenience, and patient adherence throughout a treatment period that is substantially longer than conventional symptomatic medication.
The downstream portion of the chain connects allergy diagnosis, specialist prescribing, treatment initiation, dispensing and long-term patient management. Diagnostic testing plays an unusually important role because the commercial value of an immunotherapy product depends on matching the therapy with a clinically relevant sensitizing allergen. SCIT generates greater dependence on allergy clinics and healthcare professionals for repeated administration, whereas SLIT shifts more treatment activity toward patient self-administration after appropriate medical initiation and supervision. Consequently, value is created not only through allergen production but also through product standardization, clinical evidence, dosage convenience, regulatory approval and sustained treatment adherence. These characteristics favor manufacturers with integrated capabilities spanning allergen sourcing, pharmaceutical manufacturing, quality systems and clinical development.
By allergen class, house dust mites and pollens form a broad commercial foundation because they are associated with major respiratory allergy indications, while insect-venom immunotherapy represents a more specialized but clinically important segment. Animal dander, molds and fungal allergens extend the respiratory portfolio, while food allergens represent a developing area of product innovation. From a formulation perspective, injectable extracts remain closely associated with SCIT, whereas sublingual tablets and liquid formulations support the shift toward more convenient dosing. The competitive opportunity increasingly lies in combining clinically relevant allergen coverage with standardized composition and a formulation that reduces treatment burden.
Asia presents a different opportunity structure based on locally important allergens and growing availability of standardized products. Japan has established sublingual tablet therapies targeting house dust mites and Japanese cedar pollen, demonstrating the commercial relevance of region-specific sensitization profiles. In China, the market is strongly associated with dust-mite immunotherapy, while pollen-based sublingual therapy and new dosage-form development are broadening the product landscape. The regional opportunity therefore depends less on offering a universally identical allergen portfolio and more on matching local epidemiology, regulatory requirements, physician practice and treatment accessibility.
This report is a detailed and comprehensive analysis of the world market for Allergy Immunotherapies, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Allergy Immunotherapies that contribute to its increasing demand across many markets.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Allergy Immunotherapies market
2. What is the demand of the global Allergy Immunotherapies market?
3. What is the year over year growth of the global Allergy Immunotherapies market?
4. What is the total value of the global Allergy Immunotherapies market?
5. Who are the Major Players in the global Allergy Immunotherapies market?
6. What are the growth factors driving the market demand?
Allergy Immunotherapies are disease-modifying therapeutic approaches designed to reduce allergen-specific hypersensitivity by exposing appropriately diagnosed patients to controlled doses of relevant allergens over a defined treatment course, thereby modifying the immune response rather than providing only short-term symptom control. The market covered in this study centers on subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT), and oral immunotherapy (OIT), with commercial products supplied as injectable allergen extracts, sublingual tablets, sublingual drops or solutions, and oral allergen preparations. Products may target single or multiple allergens and are developed from major allergen sources including house dust mites, pollens, insect venoms, animal dander, molds or fungi, and food allergens. Core clinical applications include allergic rhinitis and rhinoconjunctivitis, allergic asthma, Hymenoptera venom allergy, and food allergy. Product performance and commercial positioning depend strongly on allergen characterization, extract standardization, dose consistency, formulation stability, safety, administration convenience, and patient adherence throughout a treatment period that is substantially longer than conventional symptomatic medication.
Key Findings
- Disease-modifying therapy differentiates Allergy Immunotherapies from conventional symptomatic treatments
- SCIT and SLIT remain the core established administration routes globally
- Respiratory allergies anchor the established clinical application base for AIT
- Standardization and patient adherence increasingly shape product development priorities
- Food allergy is broadening the development scope of immunotherapy products
- Regional regulation materially influences available formulations and treatment models
Market Trends
The Allergy Immunotherapies market is moving toward greater product standardization, more convenient administration and increasingly allergen-specific treatment strategies. Traditional SCIT retains an important position because it supports a broad allergen portfolio and physician-controlled dosing, while SLIT tablets and liquid formulations are strengthening the home-treatment model by reducing the frequency of clinic-based administration after treatment initiation where regulations permit. Product development is increasingly focused on accurately characterized allergen extracts, consistent potency, modified allergens or allergoids, improved formulation stability and treatment schedules designed to reduce the burden of long-term therapy. The emergence of tablets and other solid sublingual dosage concepts also reflects an effort to improve dose accuracy and patient adherence. At the same time, product pipelines are gradually expanding beyond established respiratory allergens such as house dust mites and pollens toward food allergy and other areas of unmet need. These changes indicate that future competition will depend increasingly on the ability to combine clinically validated allergen specificity, standardized manufacturing and a more convenient treatment experience rather than simply expanding the number of allergen extracts offered.Market Dynamics
Drivers
The principal demand driver for Allergy Immunotherapies is their differentiated role as therapies intended to modify allergen-specific immune responses rather than provide only temporary symptom suppression. This positioning is particularly relevant for patients with persistent allergic rhinitis, rhinoconjunctivitis, allergic asthma or clinically important venom allergy whose symptoms remain burdensome despite avoidance measures and symptomatic medication. Continued improvements in allergy diagnosis also support more precise patient selection because successful immunotherapy depends on identifying allergens that are clinically relevant to an individual patient's sensitization profile. In parallel, the availability of multiple administration routes allows treatment models to address different physician and patient preferences: SCIT provides controlled clinic-based administration, while SLIT enables a greater proportion of treatment to be administered outside healthcare facilities. Expanding therapeutic development around house dust mites, pollens and selected food allergens further increases the addressable clinical opportunity for allergen-specific treatment.Restraints
The major structural restraint is the long treatment commitment required for allergen immunotherapy compared with conventional symptomatic medicines. Treatment generally requires repeated administration over an extended period, making adherence, physician follow-up and patient willingness important determinants of real-world utilization. SCIT also requires clinic-based administration and medical supervision, creating additional time and service requirements, while SLIT improves convenience but still depends on sustained adherence to regular dosing. Another constraint is the biological variability inherent in allergen source materials. Differences in allergen composition and potency make raw-material selection, extraction, characterization, stability control and standardization technically important, while regulatory requirements for efficacy and safety can differ between products and markets. These factors increase development complexity and make straightforward global product standardization more difficult than for many conventional small-molecule medicines.Opportunities
The most important opportunities are emerging from improved treatment convenience, geographic expansion of allergen-specific products and extension into areas with substantial unmet need. SLIT tablets, drops and other patient-friendly formulations can reduce dependence on frequent injection visits and may broaden access among patients who are appropriate candidates but reluctant to undertake regular clinic-based SCIT. Product opportunities also differ by local sensitization patterns: house dust mites have strong relevance in many Asian markets, while grass, tree, weed and other pollen allergens create region-specific portfolios. Japan illustrates the opportunity for highly localized allergen products through therapies targeting Japanese cedar pollen and house dust mites, while China is developing a broader portfolio around dust-mite and Artemisia-related allergies. Food allergy represents an additional long-term expansion direction, although product development and commercialization require particularly careful management of efficacy, dosing and safety.Challenges
The industry faces a combination of clinical, manufacturing and commercialization challenges. Allergy populations are heterogeneous, and sensitization identified by testing does not automatically translate into a clinically relevant treatment target, increasing the importance of patient selection and precise diagnosis. Manufacturers must maintain consistent allergen composition and biological activity despite natural variability in source materials, while also generating sufficient clinical evidence for specific allergens, formulations and treatment schedules. Commercial adoption is further affected by differences in national regulatory systems, reimbursement, prescribing habits and the organization of allergy care. SCIT, SLIT and OIT therefore do not follow a single global commercialization model. Long treatment duration also exposes manufacturers to adherence-related attrition, making treatment convenience and patient support increasingly important competitive factors. As more standardized and convenient products reach the market, legacy formulations may face greater pressure to demonstrate reproducible efficacy, quality and practical advantages.Industry Chain Analysis
The Allergy Immunotherapies industry chain begins with the controlled sourcing of allergenic biological materials, including mites, pollens, animal-derived materials, insect venoms, fungal materials and selected food allergens. These materials must then undergo extraction or preparation, purification where applicable, allergen characterization, potency determination and quality control before formulation into therapeutic products. Manufacturing complexity is higher than simple pharmaceutical blending because the biological profile of the source material directly influences the composition of the final allergen preparation. Standardization, stability testing and the preservation or modification of clinically relevant allergenic components are therefore central value-creation steps. Manufacturers subsequently convert these active preparations into injectable extracts, sublingual drops or solutions, tablets and other oral formulations under regulated pharmaceutical production systems.The downstream portion of the chain connects allergy diagnosis, specialist prescribing, treatment initiation, dispensing and long-term patient management. Diagnostic testing plays an unusually important role because the commercial value of an immunotherapy product depends on matching the therapy with a clinically relevant sensitizing allergen. SCIT generates greater dependence on allergy clinics and healthcare professionals for repeated administration, whereas SLIT shifts more treatment activity toward patient self-administration after appropriate medical initiation and supervision. Consequently, value is created not only through allergen production but also through product standardization, clinical evidence, dosage convenience, regulatory approval and sustained treatment adherence. These characteristics favor manufacturers with integrated capabilities spanning allergen sourcing, pharmaceutical manufacturing, quality systems and clinical development.
Segment Insights
By administration route, SCIT and SLIT constitute the most established parts of the Allergy Immunotherapies market, but their commercial characteristics differ substantially. SCIT supports broad allergen coverage and individualized treatment schedules and remains particularly relevant for respiratory allergens and insect venoms. SLIT, available primarily as tablets, drops and solutions depending on market regulation, offers greater convenience and can reduce the frequency of clinic visits. Within SLIT, the transition from liquid formulations toward accurately dosed solid formulations represents an important product-development direction, although liquid drops continue to support flexible allergen selection in several markets. OIT is more closely associated with food-allergy treatment and follows a distinct clinical and regulatory pathway compared with respiratory AIT.By allergen class, house dust mites and pollens form a broad commercial foundation because they are associated with major respiratory allergy indications, while insect-venom immunotherapy represents a more specialized but clinically important segment. Animal dander, molds and fungal allergens extend the respiratory portfolio, while food allergens represent a developing area of product innovation. From a formulation perspective, injectable extracts remain closely associated with SCIT, whereas sublingual tablets and liquid formulations support the shift toward more convenient dosing. The competitive opportunity increasingly lies in combining clinically relevant allergen coverage with standardized composition and a formulation that reduces treatment burden.
Downstream Market Opportunities
Respiratory allergy remains the principal established downstream opportunity for Allergy Immunotherapies, particularly in patients with allergen-driven rhinitis, rhinoconjunctivitis and allergic asthma. House dust mite and pollen therapies benefit from identifiable sensitization patterns and established SCIT and SLIT treatment models, while regional pollen profiles create opportunities for locally differentiated products. Venom allergy represents a smaller but medically important application because immunotherapy is directed toward preventing severe reactions to future stings. Food allergy offers a different growth pathway: rather than extending conventional respiratory AIT directly, it requires specialized dosing, safety management and clinical protocols. The strongest commercial opportunities are therefore likely to arise where manufacturers can match well-defined patient populations with validated allergen products and treatment formats capable of sustaining adherence over long therapy periods.Regional Insights
Regional differences are pronounced because allergen exposure patterns, regulatory frameworks and clinical practice determine which products achieve meaningful adoption. Europe supports a broad mix of SCIT and SLIT products, including injections, drops, tablets and modified allergen formulations, and has an established manufacturing base for allergen extracts. North America maintains an important role for injectable allergen extracts, while the United States also has an FDA-regulated market for specific sublingual allergen tablets; sublingual allergy drops follow a different regulatory status from approved tablets. These differences mean that the product portfolio successful in one region cannot automatically be transferred unchanged to another.Asia presents a different opportunity structure based on locally important allergens and growing availability of standardized products. Japan has established sublingual tablet therapies targeting house dust mites and Japanese cedar pollen, demonstrating the commercial relevance of region-specific sensitization profiles. In China, the market is strongly associated with dust-mite immunotherapy, while pollen-based sublingual therapy and new dosage-form development are broadening the product landscape. The regional opportunity therefore depends less on offering a universally identical allergen portfolio and more on matching local epidemiology, regulatory requirements, physician practice and treatment accessibility.
Report Scope
This report studies the global Allergy Immunotherapies demand, key companies, and key regions.This report is a detailed and comprehensive analysis of the world market for Allergy Immunotherapies, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Allergy Immunotherapies that contribute to its increasing demand across many markets.
Highlights and key features of the study
- Global Allergy Immunotherapies total market, 2021-2032, (USD Million)
- Global Allergy Immunotherapies total market by region & country, CAGR, 2021-2032, (USD Million)
- U.S. VS China: Allergy Immunotherapies total market, key domestic companies, and share, (USD Million)
- Global Allergy Immunotherapies revenue by player, revenue and market share 2021-2026, (USD Million)
- Global Allergy Immunotherapies total market by Type, CAGR, 2021-2032, (USD Million)
- Global Allergy Immunotherapies total market by Application, CAGR, 2021-2032, (USD Million)
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Allergy Immunotherapies market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.Global Allergy Immunotherapies Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
Market Segmentation
Global Allergy Immunotherapies Market, Segmentation by Type:
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
- Oral Immunotherapy (OIT)
Global Allergy Immunotherapies Market, Segmentation by Allergen Source:
- House Dust Mite Allergen Immunotherapy
- Pollen Allergen Immunotherapy
- Insect Venom Allergen Immunotherapy
- Animal Dander Allergen Immunotherapy
- Mold and Fungal Allergen Immunotherapy
- Food Allergen Immunotherapy
Global Allergy Immunotherapies Market, Segmentation by Allergen Composition:
- Single-Allergen Immunotherapy
- Multi-Allergen/Mixed-Allergen Immunotherapy
Global Allergy Immunotherapies Market, Segmentation by Application:
- Allergic Rhinitis
- Allergic Asthma
- Other
Companies Profiled:
- ALK-Abello
- Stallergenes Greer
- Merck
- Allergy Therapeutics
- HAL
- WOLW Pharma
- Holister Stier
- Leti
- Torii Pharmaceutical
- Lofarma
Key Questions Answered
1. How big is the global Allergy Immunotherapies market?2. What is the demand of the global Allergy Immunotherapies market?
3. What is the year over year growth of the global Allergy Immunotherapies market?
4. What is the total value of the global Allergy Immunotherapies market?
5. Who are the Major Players in the global Allergy Immunotherapies market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Allergy Immunotherapies Introduction
1.2 World Allergy Immunotherapies Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Allergy Immunotherapies Total Market by Region (by Headquarter Location)
1.3.1 World Allergy Immunotherapies Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.3 China Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.4 Europe Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.5 Japan Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.6 South Korea Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.7 ASEAN Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.8 India Based Company Allergy Immunotherapies Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Allergy Immunotherapies Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Allergy Immunotherapies Consumption Value (2021-2032)
2.2 World Allergy Immunotherapies Consumption Value by Region
2.2.1 World Allergy Immunotherapies Consumption Value by Region (2021-2026)
2.2.2 World Allergy Immunotherapies Consumption Value Forecast by Region (2027-2032)
2.3 United States Allergy Immunotherapies Consumption Value (2021-2032)
2.4 China Allergy Immunotherapies Consumption Value (2021-2032)
2.5 Europe Allergy Immunotherapies Consumption Value (2021-2032)
2.6 Japan Allergy Immunotherapies Consumption Value (2021-2032)
2.7 South Korea Allergy Immunotherapies Consumption Value (2021-2032)
2.8 ASEAN Allergy Immunotherapies Consumption Value (2021-2032)
2.9 India Allergy Immunotherapies Consumption Value (2021-2032)
3 WORLD ALLERGY IMMUNOTHERAPIES COMPANIES COMPETITIVE ANALYSIS
3.1 World Allergy Immunotherapies Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Allergy Immunotherapies Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Allergy Immunotherapies in 2025
3.2.3 Global Concentration Ratios (CR8) for Allergy Immunotherapies in 2025
3.3 Allergy Immunotherapies Company Evaluation Quadrant
3.4 Allergy Immunotherapies Market: Overall Company Footprint Analysis
3.4.1 Allergy Immunotherapies Market: Region Footprint
3.4.2 Allergy Immunotherapies Market: Company Product Type Footprint
3.4.3 Allergy Immunotherapies Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Allergy Immunotherapies Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Allergy Immunotherapies Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Allergy Immunotherapies Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Allergy Immunotherapies Consumption Value Comparison
4.2.1 United States VS China: Allergy Immunotherapies Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Allergy Immunotherapies Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Allergy Immunotherapies Companies and Market Share, 2021-2026
4.3.1 United States Based Allergy Immunotherapies Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Allergy Immunotherapies Revenue, (2021-2026)
4.4 China Based Companies Allergy Immunotherapies Revenue and Market Share, 2021-2026
4.4.1 China Based Allergy Immunotherapies Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Allergy Immunotherapies Revenue, (2021-2026)
4.5 Rest of World Based Allergy Immunotherapies Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Allergy Immunotherapies Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Allergy Immunotherapies Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Allergy Immunotherapies Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Subcutaneous Immunotherapy (SCIT)
5.2.2 Sublingual Immunotherapy (SLIT)
5.2.3 Oral Immunotherapy (OIT)
5.3 Market Segment by Type
5.3.1 World Allergy Immunotherapies Market Size by Type (2021-2026)
5.3.2 World Allergy Immunotherapies Market Size by Type (2027-2032)
5.3.3 World Allergy Immunotherapies Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY ALLERGEN SOURCE
6.1 World Allergy Immunotherapies Market Size Overview by Allergen Source: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Allergen Source
6.2.1 House Dust Mite Allergen Immunotherapy
6.2.2 Pollen Allergen Immunotherapy
6.2.3 Insect Venom Allergen Immunotherapy
6.2.4 Animal Dander Allergen Immunotherapy
6.2.5 Mold and Fungal Allergen Immunotherapy
6.2.6 Food Allergen Immunotherapy
6.3 Market Segment by Allergen Source
6.3.1 World Allergy Immunotherapies Market Size by Allergen Source (2021-2026)
6.3.2 World Allergy Immunotherapies Market Size by Allergen Source (2027-2032)
6.3.3 World Allergy Immunotherapies Market Size Market Share by Allergen Source (2027-2032)
7 MARKET ANALYSIS BY ALLERGEN COMPOSITION
7.1 World Allergy Immunotherapies Market Size Overview by Allergen Composition: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Allergen Composition
7.2.1 Single-Allergen Immunotherapy
7.2.2 Multi-Allergen/Mixed-Allergen Immunotherapy
7.3 Market Segment by Allergen Composition
7.3.1 World Allergy Immunotherapies Market Size by Allergen Composition (2021-2026)
7.3.2 World Allergy Immunotherapies Market Size by Allergen Composition (2027-2032)
7.3.3 World Allergy Immunotherapies Market Size Market Share by Allergen Composition (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Allergy Immunotherapies Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Allergic Rhinitis
8.2.2 Allergic Asthma
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Allergy Immunotherapies Market Size by Application (2021-2026)
8.3.2 World Allergy Immunotherapies Market Size by Application (2027-2032)
8.3.3 World Allergy Immunotherapies Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 ALK-Abello
9.1.1 ALK-Abello Details
9.1.2 ALK-Abello Major Business
9.1.3 ALK-Abello Allergy Immunotherapies Product and Services
9.1.4 ALK-Abello Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 ALK-Abello Recent Developments/Updates
9.1.6 ALK-Abello Competitive Strengths & Weaknesses
9.2 Stallergenes Greer
9.2.1 Stallergenes Greer Details
9.2.2 Stallergenes Greer Major Business
9.2.3 Stallergenes Greer Allergy Immunotherapies Product and Services
9.2.4 Stallergenes Greer Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Stallergenes Greer Recent Developments/Updates
9.2.6 Stallergenes Greer Competitive Strengths & Weaknesses
9.3 Merck
9.3.1 Merck Details
9.3.2 Merck Major Business
9.3.3 Merck Allergy Immunotherapies Product and Services
9.3.4 Merck Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Merck Recent Developments/Updates
9.3.6 Merck Competitive Strengths & Weaknesses
9.4 Allergy Therapeutics
9.4.1 Allergy Therapeutics Details
9.4.2 Allergy Therapeutics Major Business
9.4.3 Allergy Therapeutics Allergy Immunotherapies Product and Services
9.4.4 Allergy Therapeutics Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Allergy Therapeutics Recent Developments/Updates
9.4.6 Allergy Therapeutics Competitive Strengths & Weaknesses
9.5 HAL
9.5.1 HAL Details
9.5.2 HAL Major Business
9.5.3 HAL Allergy Immunotherapies Product and Services
9.5.4 HAL Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 HAL Recent Developments/Updates
9.5.6 HAL Competitive Strengths & Weaknesses
9.6 WOLW Pharma
9.6.1 WOLW Pharma Details
9.6.2 WOLW Pharma Major Business
9.6.3 WOLW Pharma Allergy Immunotherapies Product and Services
9.6.4 WOLW Pharma Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 WOLW Pharma Recent Developments/Updates
9.6.6 WOLW Pharma Competitive Strengths & Weaknesses
9.7 Holister Stier
9.7.1 Holister Stier Details
9.7.2 Holister Stier Major Business
9.7.3 Holister Stier Allergy Immunotherapies Product and Services
9.7.4 Holister Stier Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Holister Stier Recent Developments/Updates
9.7.6 Holister Stier Competitive Strengths & Weaknesses
9.8 Leti
9.8.1 Leti Details
9.8.2 Leti Major Business
9.8.3 Leti Allergy Immunotherapies Product and Services
9.8.4 Leti Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Leti Recent Developments/Updates
9.8.6 Leti Competitive Strengths & Weaknesses
9.9 Torii Pharmaceutical
9.9.1 Torii Pharmaceutical Details
9.9.2 Torii Pharmaceutical Major Business
9.9.3 Torii Pharmaceutical Allergy Immunotherapies Product and Services
9.9.4 Torii Pharmaceutical Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Torii Pharmaceutical Recent Developments/Updates
9.9.6 Torii Pharmaceutical Competitive Strengths & Weaknesses
9.10 Lofarma
9.10.1 Lofarma Details
9.10.2 Lofarma Major Business
9.10.3 Lofarma Allergy Immunotherapies Product and Services
9.10.4 Lofarma Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Lofarma Recent Developments/Updates
9.10.6 Lofarma Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Allergy Immunotherapies Industry Chain
10.2 Allergy Immunotherapies Upstream Analysis
10.3 Allergy Immunotherapies Midstream Analysis
10.4 Allergy Immunotherapies Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Allergy Immunotherapies Introduction
1.2 World Allergy Immunotherapies Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Allergy Immunotherapies Total Market by Region (by Headquarter Location)
1.3.1 World Allergy Immunotherapies Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.3 China Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.4 Europe Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.5 Japan Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.6 South Korea Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.7 ASEAN Based Company Allergy Immunotherapies Revenue (2021-2032)
1.3.8 India Based Company Allergy Immunotherapies Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Allergy Immunotherapies Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Allergy Immunotherapies Consumption Value (2021-2032)
2.2 World Allergy Immunotherapies Consumption Value by Region
2.2.1 World Allergy Immunotherapies Consumption Value by Region (2021-2026)
2.2.2 World Allergy Immunotherapies Consumption Value Forecast by Region (2027-2032)
2.3 United States Allergy Immunotherapies Consumption Value (2021-2032)
2.4 China Allergy Immunotherapies Consumption Value (2021-2032)
2.5 Europe Allergy Immunotherapies Consumption Value (2021-2032)
2.6 Japan Allergy Immunotherapies Consumption Value (2021-2032)
2.7 South Korea Allergy Immunotherapies Consumption Value (2021-2032)
2.8 ASEAN Allergy Immunotherapies Consumption Value (2021-2032)
2.9 India Allergy Immunotherapies Consumption Value (2021-2032)
3 WORLD ALLERGY IMMUNOTHERAPIES COMPANIES COMPETITIVE ANALYSIS
3.1 World Allergy Immunotherapies Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Allergy Immunotherapies Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Allergy Immunotherapies in 2025
3.2.3 Global Concentration Ratios (CR8) for Allergy Immunotherapies in 2025
3.3 Allergy Immunotherapies Company Evaluation Quadrant
3.4 Allergy Immunotherapies Market: Overall Company Footprint Analysis
3.4.1 Allergy Immunotherapies Market: Region Footprint
3.4.2 Allergy Immunotherapies Market: Company Product Type Footprint
3.4.3 Allergy Immunotherapies Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Allergy Immunotherapies Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Allergy Immunotherapies Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Allergy Immunotherapies Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Allergy Immunotherapies Consumption Value Comparison
4.2.1 United States VS China: Allergy Immunotherapies Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Allergy Immunotherapies Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Allergy Immunotherapies Companies and Market Share, 2021-2026
4.3.1 United States Based Allergy Immunotherapies Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Allergy Immunotherapies Revenue, (2021-2026)
4.4 China Based Companies Allergy Immunotherapies Revenue and Market Share, 2021-2026
4.4.1 China Based Allergy Immunotherapies Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Allergy Immunotherapies Revenue, (2021-2026)
4.5 Rest of World Based Allergy Immunotherapies Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Allergy Immunotherapies Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Allergy Immunotherapies Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Allergy Immunotherapies Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Subcutaneous Immunotherapy (SCIT)
5.2.2 Sublingual Immunotherapy (SLIT)
5.2.3 Oral Immunotherapy (OIT)
5.3 Market Segment by Type
5.3.1 World Allergy Immunotherapies Market Size by Type (2021-2026)
5.3.2 World Allergy Immunotherapies Market Size by Type (2027-2032)
5.3.3 World Allergy Immunotherapies Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY ALLERGEN SOURCE
6.1 World Allergy Immunotherapies Market Size Overview by Allergen Source: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Allergen Source
6.2.1 House Dust Mite Allergen Immunotherapy
6.2.2 Pollen Allergen Immunotherapy
6.2.3 Insect Venom Allergen Immunotherapy
6.2.4 Animal Dander Allergen Immunotherapy
6.2.5 Mold and Fungal Allergen Immunotherapy
6.2.6 Food Allergen Immunotherapy
6.3 Market Segment by Allergen Source
6.3.1 World Allergy Immunotherapies Market Size by Allergen Source (2021-2026)
6.3.2 World Allergy Immunotherapies Market Size by Allergen Source (2027-2032)
6.3.3 World Allergy Immunotherapies Market Size Market Share by Allergen Source (2027-2032)
7 MARKET ANALYSIS BY ALLERGEN COMPOSITION
7.1 World Allergy Immunotherapies Market Size Overview by Allergen Composition: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Allergen Composition
7.2.1 Single-Allergen Immunotherapy
7.2.2 Multi-Allergen/Mixed-Allergen Immunotherapy
7.3 Market Segment by Allergen Composition
7.3.1 World Allergy Immunotherapies Market Size by Allergen Composition (2021-2026)
7.3.2 World Allergy Immunotherapies Market Size by Allergen Composition (2027-2032)
7.3.3 World Allergy Immunotherapies Market Size Market Share by Allergen Composition (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Allergy Immunotherapies Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Allergic Rhinitis
8.2.2 Allergic Asthma
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Allergy Immunotherapies Market Size by Application (2021-2026)
8.3.2 World Allergy Immunotherapies Market Size by Application (2027-2032)
8.3.3 World Allergy Immunotherapies Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 ALK-Abello
9.1.1 ALK-Abello Details
9.1.2 ALK-Abello Major Business
9.1.3 ALK-Abello Allergy Immunotherapies Product and Services
9.1.4 ALK-Abello Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 ALK-Abello Recent Developments/Updates
9.1.6 ALK-Abello Competitive Strengths & Weaknesses
9.2 Stallergenes Greer
9.2.1 Stallergenes Greer Details
9.2.2 Stallergenes Greer Major Business
9.2.3 Stallergenes Greer Allergy Immunotherapies Product and Services
9.2.4 Stallergenes Greer Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Stallergenes Greer Recent Developments/Updates
9.2.6 Stallergenes Greer Competitive Strengths & Weaknesses
9.3 Merck
9.3.1 Merck Details
9.3.2 Merck Major Business
9.3.3 Merck Allergy Immunotherapies Product and Services
9.3.4 Merck Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Merck Recent Developments/Updates
9.3.6 Merck Competitive Strengths & Weaknesses
9.4 Allergy Therapeutics
9.4.1 Allergy Therapeutics Details
9.4.2 Allergy Therapeutics Major Business
9.4.3 Allergy Therapeutics Allergy Immunotherapies Product and Services
9.4.4 Allergy Therapeutics Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Allergy Therapeutics Recent Developments/Updates
9.4.6 Allergy Therapeutics Competitive Strengths & Weaknesses
9.5 HAL
9.5.1 HAL Details
9.5.2 HAL Major Business
9.5.3 HAL Allergy Immunotherapies Product and Services
9.5.4 HAL Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 HAL Recent Developments/Updates
9.5.6 HAL Competitive Strengths & Weaknesses
9.6 WOLW Pharma
9.6.1 WOLW Pharma Details
9.6.2 WOLW Pharma Major Business
9.6.3 WOLW Pharma Allergy Immunotherapies Product and Services
9.6.4 WOLW Pharma Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 WOLW Pharma Recent Developments/Updates
9.6.6 WOLW Pharma Competitive Strengths & Weaknesses
9.7 Holister Stier
9.7.1 Holister Stier Details
9.7.2 Holister Stier Major Business
9.7.3 Holister Stier Allergy Immunotherapies Product and Services
9.7.4 Holister Stier Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Holister Stier Recent Developments/Updates
9.7.6 Holister Stier Competitive Strengths & Weaknesses
9.8 Leti
9.8.1 Leti Details
9.8.2 Leti Major Business
9.8.3 Leti Allergy Immunotherapies Product and Services
9.8.4 Leti Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Leti Recent Developments/Updates
9.8.6 Leti Competitive Strengths & Weaknesses
9.9 Torii Pharmaceutical
9.9.1 Torii Pharmaceutical Details
9.9.2 Torii Pharmaceutical Major Business
9.9.3 Torii Pharmaceutical Allergy Immunotherapies Product and Services
9.9.4 Torii Pharmaceutical Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Torii Pharmaceutical Recent Developments/Updates
9.9.6 Torii Pharmaceutical Competitive Strengths & Weaknesses
9.10 Lofarma
9.10.1 Lofarma Details
9.10.2 Lofarma Major Business
9.10.3 Lofarma Allergy Immunotherapies Product and Services
9.10.4 Lofarma Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Lofarma Recent Developments/Updates
9.10.6 Lofarma Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Allergy Immunotherapies Industry Chain
10.2 Allergy Immunotherapies Upstream Analysis
10.3 Allergy Immunotherapies Midstream Analysis
10.4 Allergy Immunotherapies Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Allergy Immunotherapies Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Allergy Immunotherapies Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Allergy Immunotherapies Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Allergy Immunotherapies Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Allergy Immunotherapies Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Allergy Immunotherapies Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Allergy Immunotherapies Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Allergy Immunotherapies Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Allergy Immunotherapies Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Allergy Immunotherapies Players in 2025
Table 12. World Allergy Immunotherapies Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Allergy Immunotherapies Company Evaluation Quadrant
Table 14. Head Office of Key Allergy Immunotherapies Players
Table 15. Allergy Immunotherapies Market: Company Product Type Footprint
Table 16. Allergy Immunotherapies Market: Company Product Application Footprint
Table 17. Allergy Immunotherapies Mergers & Acquisitions Activity
Table 18. United States VS China Allergy Immunotherapies Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Allergy Immunotherapies Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Allergy Immunotherapies Companies, Headquarters (States, Country)
Table 21. United States Based Companies Allergy Immunotherapies Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Allergy Immunotherapies Revenue Market Share (2021-2026)
Table 23. China Based Allergy Immunotherapies Companies, Headquarters (Province, Country)
Table 24. China Based Companies Allergy Immunotherapies Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Allergy Immunotherapies Revenue Market Share (2021-2026)
Table 26. Rest of World Based Allergy Immunotherapies Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Allergy Immunotherapies Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Allergy Immunotherapies Revenue Market Share (2021-2026)
Table 29. World Allergy Immunotherapies Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Allergy Immunotherapies Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Allergy Immunotherapies Market Size by Type (2027-2032) & (USD Million)
Table 32. World Allergy Immunotherapies Market Size by Allergen Source, (USD Million), 2021 & 2025 & 2032
Table 33. World Allergy Immunotherapies Market Size Value by Allergen Source (2021-2026) & (USD Million)
Table 34. World Allergy Immunotherapies Market Size by Allergen Source (2027-2032) & (USD Million)
Table 35. World Allergy Immunotherapies Market Size by Allergen Composition, (USD Million), 2021 & 2025 & 2032
Table 36. World Allergy Immunotherapies Market Size Value by Allergen Composition (2021-2026) & (USD Million)
Table 37. World Allergy Immunotherapies Market Size by Allergen Composition (2027-2032) & (USD Million)
Table 38. World Allergy Immunotherapies Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Allergy Immunotherapies Market Size by Application (2021-2026) & (USD Million)
Table 40. World Allergy Immunotherapies Market Size by Application (2027-2032) & (USD Million)
Table 41. ALK-Abello Basic Information, Manufacturing Base and Competitors
Table 42. ALK-Abello Major Business
Table 43. ALK-Abello Allergy Immunotherapies Product and Services
Table 44. ALK-Abello Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. ALK-Abello Recent Developments/Updates
Table 46. ALK-Abello Competitive Strengths & Weaknesses
Table 47. Stallergenes Greer Basic Information, Manufacturing Base and Competitors
Table 48. Stallergenes Greer Major Business
Table 49. Stallergenes Greer Allergy Immunotherapies Product and Services
Table 50. Stallergenes Greer Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Stallergenes Greer Recent Developments/Updates
Table 52. Stallergenes Greer Competitive Strengths & Weaknesses
Table 53. Merck Basic Information, Manufacturing Base and Competitors
Table 54. Merck Major Business
Table 55. Merck Allergy Immunotherapies Product and Services
Table 56. Merck Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Merck Recent Developments/Updates
Table 58. Merck Competitive Strengths & Weaknesses
Table 59. Allergy Therapeutics Basic Information, Manufacturing Base and Competitors
Table 60. Allergy Therapeutics Major Business
Table 61. Allergy Therapeutics Allergy Immunotherapies Product and Services
Table 62. Allergy Therapeutics Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Allergy Therapeutics Recent Developments/Updates
Table 64. Allergy Therapeutics Competitive Strengths & Weaknesses
Table 65. HAL Basic Information, Manufacturing Base and Competitors
Table 66. HAL Major Business
Table 67. HAL Allergy Immunotherapies Product and Services
Table 68. HAL Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. HAL Recent Developments/Updates
Table 70. HAL Competitive Strengths & Weaknesses
Table 71. WOLW Pharma Basic Information, Manufacturing Base and Competitors
Table 72. WOLW Pharma Major Business
Table 73. WOLW Pharma Allergy Immunotherapies Product and Services
Table 74. WOLW Pharma Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. WOLW Pharma Recent Developments/Updates
Table 76. WOLW Pharma Competitive Strengths & Weaknesses
Table 77. Holister Stier Basic Information, Manufacturing Base and Competitors
Table 78. Holister Stier Major Business
Table 79. Holister Stier Allergy Immunotherapies Product and Services
Table 80. Holister Stier Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Holister Stier Recent Developments/Updates
Table 82. Holister Stier Competitive Strengths & Weaknesses
Table 83. Leti Basic Information, Manufacturing Base and Competitors
Table 84. Leti Major Business
Table 85. Leti Allergy Immunotherapies Product and Services
Table 86. Leti Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Leti Recent Developments/Updates
Table 88. Leti Competitive Strengths & Weaknesses
Table 89. Torii Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 90. Torii Pharmaceutical Major Business
Table 91. Torii Pharmaceutical Allergy Immunotherapies Product and Services
Table 92. Torii Pharmaceutical Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Torii Pharmaceutical Recent Developments/Updates
Table 94. Torii Pharmaceutical Competitive Strengths & Weaknesses
Table 95. Lofarma Basic Information, Manufacturing Base and Competitors
Table 96. Lofarma Major Business
Table 97. Lofarma Allergy Immunotherapies Product and Services
Table 98. Lofarma Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Lofarma Recent Developments/Updates
Table 100. Lofarma Competitive Strengths & Weaknesses
Table 101. Global Key Players of Allergy Immunotherapies Upstream (Raw Materials)
Table 102. Global Allergy Immunotherapies Typical Customers
Table 1. World Allergy Immunotherapies Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Allergy Immunotherapies Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Allergy Immunotherapies Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Allergy Immunotherapies Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Allergy Immunotherapies Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Allergy Immunotherapies Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Allergy Immunotherapies Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Allergy Immunotherapies Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Allergy Immunotherapies Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Allergy Immunotherapies Players in 2025
Table 12. World Allergy Immunotherapies Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Allergy Immunotherapies Company Evaluation Quadrant
Table 14. Head Office of Key Allergy Immunotherapies Players
Table 15. Allergy Immunotherapies Market: Company Product Type Footprint
Table 16. Allergy Immunotherapies Market: Company Product Application Footprint
Table 17. Allergy Immunotherapies Mergers & Acquisitions Activity
Table 18. United States VS China Allergy Immunotherapies Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Allergy Immunotherapies Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Allergy Immunotherapies Companies, Headquarters (States, Country)
Table 21. United States Based Companies Allergy Immunotherapies Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Allergy Immunotherapies Revenue Market Share (2021-2026)
Table 23. China Based Allergy Immunotherapies Companies, Headquarters (Province, Country)
Table 24. China Based Companies Allergy Immunotherapies Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Allergy Immunotherapies Revenue Market Share (2021-2026)
Table 26. Rest of World Based Allergy Immunotherapies Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Allergy Immunotherapies Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Allergy Immunotherapies Revenue Market Share (2021-2026)
Table 29. World Allergy Immunotherapies Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Allergy Immunotherapies Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Allergy Immunotherapies Market Size by Type (2027-2032) & (USD Million)
Table 32. World Allergy Immunotherapies Market Size by Allergen Source, (USD Million), 2021 & 2025 & 2032
Table 33. World Allergy Immunotherapies Market Size Value by Allergen Source (2021-2026) & (USD Million)
Table 34. World Allergy Immunotherapies Market Size by Allergen Source (2027-2032) & (USD Million)
Table 35. World Allergy Immunotherapies Market Size by Allergen Composition, (USD Million), 2021 & 2025 & 2032
Table 36. World Allergy Immunotherapies Market Size Value by Allergen Composition (2021-2026) & (USD Million)
Table 37. World Allergy Immunotherapies Market Size by Allergen Composition (2027-2032) & (USD Million)
Table 38. World Allergy Immunotherapies Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Allergy Immunotherapies Market Size by Application (2021-2026) & (USD Million)
Table 40. World Allergy Immunotherapies Market Size by Application (2027-2032) & (USD Million)
Table 41. ALK-Abello Basic Information, Manufacturing Base and Competitors
Table 42. ALK-Abello Major Business
Table 43. ALK-Abello Allergy Immunotherapies Product and Services
Table 44. ALK-Abello Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. ALK-Abello Recent Developments/Updates
Table 46. ALK-Abello Competitive Strengths & Weaknesses
Table 47. Stallergenes Greer Basic Information, Manufacturing Base and Competitors
Table 48. Stallergenes Greer Major Business
Table 49. Stallergenes Greer Allergy Immunotherapies Product and Services
Table 50. Stallergenes Greer Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Stallergenes Greer Recent Developments/Updates
Table 52. Stallergenes Greer Competitive Strengths & Weaknesses
Table 53. Merck Basic Information, Manufacturing Base and Competitors
Table 54. Merck Major Business
Table 55. Merck Allergy Immunotherapies Product and Services
Table 56. Merck Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Merck Recent Developments/Updates
Table 58. Merck Competitive Strengths & Weaknesses
Table 59. Allergy Therapeutics Basic Information, Manufacturing Base and Competitors
Table 60. Allergy Therapeutics Major Business
Table 61. Allergy Therapeutics Allergy Immunotherapies Product and Services
Table 62. Allergy Therapeutics Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Allergy Therapeutics Recent Developments/Updates
Table 64. Allergy Therapeutics Competitive Strengths & Weaknesses
Table 65. HAL Basic Information, Manufacturing Base and Competitors
Table 66. HAL Major Business
Table 67. HAL Allergy Immunotherapies Product and Services
Table 68. HAL Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. HAL Recent Developments/Updates
Table 70. HAL Competitive Strengths & Weaknesses
Table 71. WOLW Pharma Basic Information, Manufacturing Base and Competitors
Table 72. WOLW Pharma Major Business
Table 73. WOLW Pharma Allergy Immunotherapies Product and Services
Table 74. WOLW Pharma Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. WOLW Pharma Recent Developments/Updates
Table 76. WOLW Pharma Competitive Strengths & Weaknesses
Table 77. Holister Stier Basic Information, Manufacturing Base and Competitors
Table 78. Holister Stier Major Business
Table 79. Holister Stier Allergy Immunotherapies Product and Services
Table 80. Holister Stier Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Holister Stier Recent Developments/Updates
Table 82. Holister Stier Competitive Strengths & Weaknesses
Table 83. Leti Basic Information, Manufacturing Base and Competitors
Table 84. Leti Major Business
Table 85. Leti Allergy Immunotherapies Product and Services
Table 86. Leti Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Leti Recent Developments/Updates
Table 88. Leti Competitive Strengths & Weaknesses
Table 89. Torii Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 90. Torii Pharmaceutical Major Business
Table 91. Torii Pharmaceutical Allergy Immunotherapies Product and Services
Table 92. Torii Pharmaceutical Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Torii Pharmaceutical Recent Developments/Updates
Table 94. Torii Pharmaceutical Competitive Strengths & Weaknesses
Table 95. Lofarma Basic Information, Manufacturing Base and Competitors
Table 96. Lofarma Major Business
Table 97. Lofarma Allergy Immunotherapies Product and Services
Table 98. Lofarma Allergy Immunotherapies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Lofarma Recent Developments/Updates
Table 100. Lofarma Competitive Strengths & Weaknesses
Table 101. Global Key Players of Allergy Immunotherapies Upstream (Raw Materials)
Table 102. Global Allergy Immunotherapies Typical Customers
LIST OF FIGURES
Figure 1. Allergy Immunotherapies Picture
Figure 2. World Allergy Immunotherapies Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Allergy Immunotherapies Total Revenue (2021-2032) & (USD Million)
Figure 4. World Allergy Immunotherapies Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Allergy Immunotherapies Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 13. Allergy Immunotherapies Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 16. World Allergy Immunotherapies Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 18. China Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 23. India Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Allergy Immunotherapies by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Allergy Immunotherapies Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Allergy Immunotherapies Markets in 2025
Figure 27. United States VS China: Allergy Immunotherapies Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Allergy Immunotherapies Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Allergy Immunotherapies Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Allergy Immunotherapies Market Size Market Share by Type in 2025
Figure 31. Subcutaneous Immunotherapy (SCIT)
Figure 32. Sublingual Immunotherapy (SLIT)
Figure 33. Oral Immunotherapy (OIT)
Figure 34. World Allergy Immunotherapies Market Size Market Share by Type (2021-2032)
Figure 35. World Allergy Immunotherapies Market Size by Allergen Source, (USD Million), 2021 & 2025 & 2032
Figure 36. World Allergy Immunotherapies Market Size Market Share by Allergen Source in 2025
Figure 37. House Dust Mite Allergen Immunotherapy
Figure 38. Pollen Allergen Immunotherapy
Figure 39. Insect Venom Allergen Immunotherapy
Figure 40. Animal Dander Allergen Immunotherapy
Figure 41. Mold and Fungal Allergen Immunotherapy
Figure 42. Food Allergen Immunotherapy
Figure 43. World Allergy Immunotherapies Market Size Market Share by Allergen Source (2021-2032)
Figure 44. World Allergy Immunotherapies Market Size by Allergen Composition, (USD Million), 2021 & 2025 & 2032
Figure 45. World Allergy Immunotherapies Market Size Market Share by Allergen Composition in 2025
Figure 46. Single-Allergen Immunotherapy
Figure 47. Multi-Allergen/Mixed-Allergen Immunotherapy
Figure 48. World Allergy Immunotherapies Market Size Market Share by Allergen Composition (2021-2032)
Figure 49. World Allergy Immunotherapies Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 50. World Allergy Immunotherapies Market Size Market Share by Application in 2025
Figure 51. Allergic Rhinitis
Figure 52. Allergic Asthma
Figure 53. Other
Figure 54. World Allergy Immunotherapies Market Size Market Share by Application (2021-2032)
Figure 55. Allergy Immunotherapies Industrial Chain
Figure 56. Methodology
Figure 57. Research Process and Data Source
Figure 1. Allergy Immunotherapies Picture
Figure 2. World Allergy Immunotherapies Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Allergy Immunotherapies Total Revenue (2021-2032) & (USD Million)
Figure 4. World Allergy Immunotherapies Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Allergy Immunotherapies Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Allergy Immunotherapies Revenue (2021-2032) & (USD Million)
Figure 13. Allergy Immunotherapies Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 16. World Allergy Immunotherapies Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 18. China Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 23. India Allergy Immunotherapies Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Allergy Immunotherapies by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Allergy Immunotherapies Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Allergy Immunotherapies Markets in 2025
Figure 27. United States VS China: Allergy Immunotherapies Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Allergy Immunotherapies Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Allergy Immunotherapies Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Allergy Immunotherapies Market Size Market Share by Type in 2025
Figure 31. Subcutaneous Immunotherapy (SCIT)
Figure 32. Sublingual Immunotherapy (SLIT)
Figure 33. Oral Immunotherapy (OIT)
Figure 34. World Allergy Immunotherapies Market Size Market Share by Type (2021-2032)
Figure 35. World Allergy Immunotherapies Market Size by Allergen Source, (USD Million), 2021 & 2025 & 2032
Figure 36. World Allergy Immunotherapies Market Size Market Share by Allergen Source in 2025
Figure 37. House Dust Mite Allergen Immunotherapy
Figure 38. Pollen Allergen Immunotherapy
Figure 39. Insect Venom Allergen Immunotherapy
Figure 40. Animal Dander Allergen Immunotherapy
Figure 41. Mold and Fungal Allergen Immunotherapy
Figure 42. Food Allergen Immunotherapy
Figure 43. World Allergy Immunotherapies Market Size Market Share by Allergen Source (2021-2032)
Figure 44. World Allergy Immunotherapies Market Size by Allergen Composition, (USD Million), 2021 & 2025 & 2032
Figure 45. World Allergy Immunotherapies Market Size Market Share by Allergen Composition in 2025
Figure 46. Single-Allergen Immunotherapy
Figure 47. Multi-Allergen/Mixed-Allergen Immunotherapy
Figure 48. World Allergy Immunotherapies Market Size Market Share by Allergen Composition (2021-2032)
Figure 49. World Allergy Immunotherapies Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 50. World Allergy Immunotherapies Market Size Market Share by Application in 2025
Figure 51. Allergic Rhinitis
Figure 52. Allergic Asthma
Figure 53. Other
Figure 54. World Allergy Immunotherapies Market Size Market Share by Application (2021-2032)
Figure 55. Allergy Immunotherapies Industrial Chain
Figure 56. Methodology
Figure 57. Research Process and Data Source
